KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Decroos A, Cheminant M, Bruneau J, Carras S, et al. Haematologica 2023 May 11. doi: 10.3324/haematol.2022.282220.

Read + Share

Amedeo Smart

Independent Medical Education

Decroos A, Cheminant M, Bruneau J, Carras S, et al. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Haematologica 2023 May 11. doi: 10.3324/haematol.2022.282220.
PMID: 37165836